This invention relates to novel 3-substituted quinuclidine derivatives,
which are found to be cholinergic ligands at the nicotinic acetylcholine
receptors and modulators of the monoamine receptors and transporters. Due
to their pharmacological profile the compounds of the invention may be
useful for the treatment of diseases or disorders as diverse as those
related to the cholinergic system of the central nervous system (CNS),
the peripheral nervous system (PNS), diseases or disorders related to
smooth muscle contraction, endocrine diseases or disorders, diseases or
disorders related to neurodegeneration, diseases or disorders related to
inflammation, pain, and withdrawal symptoms caused by the termination of
abuse of chemical substances.
